MedTrace Logo

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

NCT03516110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 831

Last updated 2026-01-23

No results posted yet for this study

Summary

The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.

Conditions

Interventions

OTHER

Data collection

Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-09
Primary Completion
2020-02-28
Completion
2020-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516110 on ClinicalTrials.gov